Abstract: A modified cutinase is disclosed. The cutinase has the modified amino acid sequence of SEQ ID NO: 2, wherein the modification is a substitution of asparagine at position 181 with alanine, or substitutions of asparagine at position 181 with alanine and phenylalanine at position 235 with leucine. The modified enzyme has improved PET-hydrolytic activity, and thus, the high-activity PET hydrolase is obtained, and the industrial application value of the PET hydrolase is enhanced.

Abstract: The present invention discloses a fabrication method and use of a ?40 mm large-size and high-contrast fiber optic image inverter, belonging to the field of manufacturing of fiber optic imaging elements. The light-absorbing glass for preparing the ?40 mm large-size and high-contrast fiber optic image inverter consists of the following components in molar percentage: SiO2 60-69.9, Al2O3 1.0-10.0, B2O3 10.1-15.0, Na2O 1.0-8.0, K2O 3.0-10.0, MgO 0.1-1.0, CaO 0.5-5.0, ZnO 0-0.1, TiO2 0-0.1, ZrO2 0.1-1.0, Fe2O3 3.0-6.5, Co2O3 0.1-0.5, V2O5 0.51-1.5 and MoO3 0.1-1.0. The fiber optic image inverter has the advantages of low crosstalk of stray light, high resolution and high contrast.

Abstract: A method for evaluating rock drillability by a nano-indentation test on a rock cutting includes: conducting a nano-indentation test on a rock cutting sample, acquiring a displacement-load curve of an indenter, and calculating a micro-hardness under the nano-indentation test; calculating mineral composition of the rock cutting sample based on a statistical distribution characteristic of the micro-hardness, and transforming the micro-hardness under the nano-indentation test on the rock cutting sample into a macro-hardness; and calculating a rock drillability grade characterized by the micro-hardness under the nano-indentation test on the rock cutting sample based on a correlation between the macro-hardness of the rock cutting sample and the rock drillability grade. In the context of few downhole rock samples and high cost, the method overcomes the limitation of sample size and shape on conventional testing and solves the difficult problem of mechanical parameter testing of deep rocks.

Abstract: The present disclosure relates to the technical field of oil-gas field development, and discloses a shale oil fracturing synchronous energizing simulation experimental device and method. The shale oil fracturing synchronous energizing simulation experimental device comprises a liquid supply system, a confining pressure loading system, a fracturing system, an energizing system and a recovery system, wherein the liquid supply system is used for storing fluid and can inject the fluid into the fracturing system; the fracturing system can bear a test piece, receive the fluid injected by the liquid supply system and serve as seepage space of the fluid; the confining pressure loading system is used for providing simulated confining pressure for the test piece; the energizing system is used for simulating an energizing effect on a test piece after fracturing liquid is injected; and the recovery system is used for collecting discharged liquid and separating and metering the discharged liquid.

Abstract: The present disclosure relates to the technical field of oil-gas field development, and discloses a shale oil fracturing synchronous energizing simulation experimental device and method. The shale oil fracturing synchronous energizing simulation experimental device comprises a liquid supply system, a confining pressure loading system, a fracturing system, an energizing system and a recovery system, wherein the liquid supply system is used for storing fluid and can inject the fluid into the fracturing system; the fracturing system can bear a test piece, receive the fluid injected by the liquid supply system and serve as seepage space of the fluid; the confining pressure loading system is used for providing simulated confining pressure for the test piece; the energizing system is used for simulating an energizing effect on a test piece after fracturing liquid is injected; and the recovery system is used for collecting discharged liquid and separating and metering the discharged liquid.

Abstract: The present invention relates to the photocatalyst field, and discloses a photocatalyst for removing hydroxypropyl guar gum in flow-back fluid of fracturing liquid, and a preparation method and the use of the photocatalyst, wherein, the photocatalyst is expressed by Bi5O7Br0.5I0.5, in a powder form in 12-15 nm particle size, with 285-300 m2/g specific surface area. The photocatalyst has improved response to visible light, has greater specific surface area, and has very high activity in removal of hydroxypropyl guar gum in flow-back fluid of fracturing liquid. In addition, the photocatalyst can be prepared with a simple preparation method under mild conditions, and can be used to remove hydroxypropyl guar gum in flow-back fluid of fracturing liquid.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR1R1a, or O—R1, wherein X is H, halo, C1-C6 alkyl, NO2, mono-, di-, or tri-halo substituted methyl, NR13R,14.

Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.

Abstract: A compound according to Formula IV: or a pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof, wherein R1, R2, R3, R4, R5 and X are as defined in the specification.

Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.

Abstract: This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Abstract: The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein, V is NR1R1a, or O—R1, wherein X is H, halo, C1-C6 alkyl, NO2, mono-, di-, or tri-halo substituted methyl, NR13R,14.

Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.